A new study reveals that patients diagnosed with Type2-diabetes are at an increased risk of developing macrovascular and microvascular complications. Researchers are currently using a drug called Linagliptin which is an anti-diabetic drug that works by increasing the levels of incretins to help control blood sugar levels, especially after meals.
According to reports, the cardiovascular outcome trials using Linagliptin are currently being carried out and it will take a few years before the results are available. However, one well-known cardiovascular surrogate parameter is endothelial dysfunction. Research has shown that endothelial dysfunction is present in patients with early diabetes and can be improved with the help of pharmacological interventions. According to the researchers, the surrogate measurement could prove to be helpful in getting a better understanding of the cardiovascular effects of Linagliptin.
UKPDS (United Kingdom Prospective Diabetes Study) post trial monitoring highlighted the importance of an early glucose lowering intervention in patients with T2DM with respect to micro- and macrovascular complications. The aim of the study has been to further investigate the effects of Linagliptin in coronary patients who have Type-2 diabetes on cardiovascular surrogate measurements along with mechanical and biochemical endothelial assessments.
As the top suppliers of API products for the research and development of anti-diabetic drugs, LGM Pharma supplies high quality Linagliptin CAS# 668270-12-0 for future drug development studies.
General Drug Facts
Linagliptin is used along with a suitable diet and exercise program and sometimes along with other medications to control high blood sugar levels. It is normally used by those people who have been diagnosed with Type-2 diabetes. Controlling high blood sugar is important since it prevents kidney damage, nerve problems, blindness and a loss of function of limbs. Results in 2010 from a Phase III clinical trial of Linagliptin showed that it is highly effective when it comes to reducing blood sugar levels.
General Disease Facts
Type 2 diabetes is common among middle-aged and older adults, but it has also been found in younger people too. Type-2 diabetes is characterized by a high blood glucose level which is caused by either the body’s inability to use insulin properly or the lack of insulin in the body.
- “Effects of Linagliptin on Endothelial Function” U.S. National Library of Medicine Oct. 2015. https://clinicaltrials.gov/ct2/show/NCT02350478
- “Linagliptin launched for type 2 diabetes” The Pharmaceutical Journal 21 Sep. 2011. http://www.pharmaceutical-journal.com/news-and-analysis/news/linagliptin-launched-for-type-2-diabetes/11084733.article
- Edoardo Mannucci, MD, Ilaria Dicembrini, MD, Angelo Lauria, MD and Paolo Pozzilli, MD. “Is Glucose Control Important for Prevention of Cardiovascular Disease in Diabetes?” American Diabetes Association. http://care.diabetesjournals.org/content/36/Supplement_2/S259.full
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.